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ABSTRACT 
 
Osteosarcoma is a malignant bone tumor predominantly affecting children 
and adolescents. Osteosarcoma has a 60-70% survival rate with current 
treatments; hence there is a need to identify novel adjuncts to chemotherapeutic 
regimens. The active form of vitamin D, 1α,25-dihydroxyvitamin D3 (1,25D), is 
being increasingly recognized for its anti-cancer properties. The dose-response 
of 1,25D and 25-hydroxyvitamin D3 (25D) was examined on human 
osteosarcoma cell lines, SaOS-2 (tumorigenic, p53 null, metastatic) and 143B 
(tumorigenic, ras gene transformed and highly metastatic). It was hypothesized 
that both forms of vitamin D would inhibit proliferation, stimulate differentiation 
and induce apoptosis of these cells in a dose-dependent manner. Osteosarcoma 
cell lines, SaOS-2 and 143B, were treated with 1,25D, 25D or an ethanol control 
respectively at concentrations ranging from 1-1000nM. Cellular proliferation was 
measured after 1,25D or 25D exposure using a cell viability assay (MTS), Ki67 
immunocytochemistry and cell cycle analysis by flow cytometry. Osteoblastic 
differentiation was measured by alkaline phosphatase (ALP) activity, osteocalcin 
secretion and in vitro osteoblastic mineralization. Apoptosis was determined by 
Terminal Deoxynucleotide Transferase dUTP Nick End Labeling (TUNEL).  
Neither 25D nor 1,25D inhibited proliferation or affected cell cycle in SaOS-2 or 
143B cells, although in 143B cells, proliferation was increased significantly in 
cells exposed to 25D at 1000nM versus control. Markers of osteoblastic 
differentiation were upregulated. In particular, a significant increase in ALP in 
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143B cells and mineralization in SaOS-2 and 143B cells was observed. The 
effect of 1,25D on apoptosis in SaOS-2 and 143B cells was not significant; 25D 
at high concentration (1000nM) increased numbers of apoptotic cells significantly 
(p<0.05). Biological differences between SaOS-2 and 143B control cells were 
observed. Cell cycle analysis revealed significantly more SaOS-2 control cells in 
G0/G1 than 143B, and significantly fewer SaOS-2 cells in synthesis phase than 
143B (p<0.05). SaOS-2 control cells had ALP levels significantly higher than 
143B cells (p<0.05).   Both forms of vitamin D (25D and 1,25D) did not inhibit 
proliferation but acted as differentiation agents in SaOS-2 and 143B cells through 
activation or upregulation of markers of osteoblastic differentiation, including ALP 
and/or osteoblastic mineralization. At high concentration (1000nM), 25D 
increases apoptosis. There are also inherent differences in the biology of SaOS-
2 and 143B osteosarcoma cells which modulate 1,25D response. 
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CHAPTERS
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CHAPTER 1 INTRODUCTION 
 
Osteosarcoma is a malignant bone tumor predominantly affecting children 
and adolescents (1).  Current treatment regimens do not significantly improve the 
present 60-70% survival rate.  Therapies in osteosarcoma have remained 
relatively unchanged over the past 20 years (2, 3).  There is a need to identify 
novel therapeutic regimens to improve survival rates for those individuals with 
ineffective treatments.  
The active form of vitamin D, 1α,25-dihdroxyvitamin D3 (1,25D) is 
increasingly recognized for its anti-cancer properties (4, 5). The main biologic 
function of 1,25D is to maintain serum calcium levels within normal range by 
increasing the efficiency of intestinal absorption of dietary calcium (6, 7) and 
mobilizing calcium stores from the bone into circulation (8-10).  Extra-skeletal 
cells and tissues produce 1,25D (7).  By binding to the nuclear vitamin D receptor 
(VDR), 1,25D regulates expression of genes responsible for cellular proliferation, 
differentiation, apoptosis and angiogenesis in local tissues (11, 12).  In vitro and 
in vivo, 1,25D induces anti-neoplastic activity in tumors of the colon (13, 14), 
prostate (15-17) and breast (18).  
In human osteosarcoma cells, 1,25D inhibits cell proliferation at 
concentrations 0.1-100nM in a time- and dose-dependent manner (11, 19-28).  
At concentrations of 10nM-100nM, 1,25D enhances the differentiation of 
osteosarcoma cell lines into cells that exhibit properties of mature osteoblasts 
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(20, 21, 23, 24, 26, 28-31).  In human osteosarcoma cells, 1,25D stimulates the 
expression of markers of osteoblastic differentiation, including osteocalcin (21-
25, 27, 30, 31), alkaline phosphatase (20, 21, 26, 28, 30, 31), and mineralization 
(25, 29) through incorporation of calcium into the extracellular matrix.  Type I 
collagen is expressed after exposure to 1,25D (29, 32, 33) early in differentiation 
of osteosarcoma cells.  
The mechanisms by which 1,25D regulates proliferation and differentiation 
in osteosarcoma are not completely understood. Several studies suggest 1,25D 
exerts an antiproliferative effect by arresting cells in the G1 phase of the cell 
cycle (20, 24, 27, 28).  It is postulated that G1 arrest might be due to an 
antiapoptotic effect (34), an antiproliferative effect (24) or a combination of both.   
Evidence that 1,25D induces apoptosis in canine osteosarcoma cells 
comes from TUNEL studies detecting DNA fragmentation, a hallmark of apoptotic 
cells (33, 35).  Studies in rodent and human osteosarcoma cell lines are 
contradictory. These studies show that 1,25D either inhibits (26, 34) or have no 
effect on apoptosis (22, 23). Numerous signaling pathways are regulated by 
1,25D and 1,25D-induced apoptosis varies among cell types (19, 20, 28).  
Further study is necessary to explore these pathways and the role of 1,25D in 
modulating apoptosis of osteosarcoma cells. 
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Justification for Further Investigation 
There are significant unknowns and contradictions in current literature on 
1,25D and osteosarcoma.  The dose-response of 1,25D on different 
osteosarcoma cells is not well-identified.  The mechanisms involving inhibition of 
proliferation and promotion of differentiation remain unclear.  The effects of 
1,25D on apoptosis in osteosarcoma cells are particularly contradictory, 
warranting further investigation, including examination of pro- and anti-apoptotic 
protein expression. 
The potential of the inactive form of vitamin D, 25-hydroxyvitamin D3 
(25D), to locally convert to active 1,25D and inhibit tumorigenesis and 
progression is a new finding (7, 25).  The effect of exogenous 25D on these 
cellular processes in human osteosarcoma cells is not clearly defined.  The 
effects of 1,25D or 25D on 143B, a highly metastatic human osteosarcoma cell 
line, remain largely unknown.  Given that osteosarcoma is a highly aggressive 
and malignant disease, results with regard to this cell line are of significant 
interest.  
A better understanding of the underlying mechanisms of disease is 
important to identify targets for devising novel therapies given the prevalence of 
osteosarcoma in children and adolescents.  The results from this in vitro study 
will provide the foundation for future studies using in vivo animal models and in 
clinical chemotherapy and treatment. 
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Statement of Purpose  
The objectives of this study were:  
a) to determine the dose-response of vitamin D (25D or 1,25D) on 
osteosarcoma cell lines 
b) to identify the effects of vitamin D (25D or 1,25D) on cellular processes 
in osteosarcoma cells 
 
Research Questions 
 Primary Question:   
What is the dose-dependent response of vitamin D, (25D or 1,25D) 
on osteosarcoma cell lines, SaOS-2 and 143B? 
Secondary Questions: 
1. What is the in vitro effect of vitamin D (25D or 1,25D) on cellular 
proliferation in human osteosarcoma? 
2.  What is the in vitro effect of vitamin D (25D or 1,25D) on differentiation 
in human osteosarcoma, as analyzed by expression of differentiation 
markers osteocalcin, alkaline phosphatase and mineralization 
competence?  
3. What is the effect of vitamin D (25D or 1,25D) on apoptosis in human 
osteosarcoma cells? 
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Hypothesis 
 
  It is hypothesized that vitamin D (both 25D and 1,25D) will inhibit 
proliferation, stimulate differentiation and induce apoptosis of human 
osteosarcoma cell lines in a dose-dependent manner.  
 
 
 
 
 
FIGURE 1. Hypothesis schematic 
 
OR 
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CHAPTER 2 LITERATURE REVIEW 
 
Osteosarcoma 
Osteosarcoma is a malignant bone tumor predominantly affecting children 
and adolescents (1, 36, 37).  Osteosarcoma is associated with lung metastases, 
characterized by uncontrolled proliferation, insensitivity to growth inhibitory 
signals and evasion of apoptosis (1, 19).  As with many other forms of cancer, its 
etiology is not known and is likely multifactorial.   
Prior to the introduction of chemotherapy, osteosarcoma survival rates 
were only 10% to 20%.  Surgical resection, usually amputation, was the only 
treatment available (3, 36-40).  More recently, chemotherapy regimens combined 
with surgical resection have resulted in improved patient outcomes (41, 42). 
Long-term survival rates are now 60% to 70% in patients with localized disease 
(2, 3).  The most effective chemotherapeutic agents for OS treatment include 
high-dose methotrexate, cisplatin, doxorubicin, etoposide and ifosfamide.  All are 
associated with toxicities (43, 44) and may induce debilitating side effects (3). 
Patients who present with metastatic disease have only a 20% to 30% survival 
rate five years after diagnosis regardless of treatment (2, 3, 37).  
Chemotherapeutic efficacy and patient survival has reached a plateau with 
currently available treatments.  New treatment regimens and novel adjuncts to 
chemotherapy are necessary for those patients with ineffective treatment 
regimens. The active form of vitamin D could be a novel adjunct to chemotherapy 
improving survival rates and decreasing toxicity observed in osteosarcoma.   
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Vitamin D 
Vitamin D is a secosteriod humans acquire from their diet, dietary 
supplements and exposure to sunlight.  Upon ingestion or absorption through the 
skin, the biologically inert vitamin D3 is hydroxylated in the liver to form 25D (8, 9, 
45).  In the kidney, 25D is further hydroxylated by the enzyme 25D-1α-
hydroxylase into its active form, 1,25D (8-9, 45).  The major circulating metabolite 
of vitamin D is 25D and blood levels serve as the best indicator for vitamin D 
status (25).  Since the kidneys tightly regulate the production of 1,25D, serum 
levels do not rise in response to increased exposure to sunlight or increased 
intake of vitamin D (8). 
The main biologic function of 1,25D is to maintain serum calcium levels 
within normal range. It increases the efficiency of intestinal absorption of dietary 
calcium (6, 7) and mobilizes calcium stores from the bone into the circulation 
through the action of osteoclasts (8-10).  In addition to its calcemic actions, 
1,25D and its analogues are now recognized to influence regulation of the cell-
cycle (4, 5).  While the kidneys are the source of circulating levels of 1,25D (8, 9, 
45), bone and other extra-renal tissues synthesize 1,25D (25, 46).  This locally 
produced 1,25D can bind to the VDR and activate or repress gene expression 
through 1,25D-responsive elements located in the promoter regions of various 
target genes (11).  In an autocrine or paracrine manner, 1,25D influences more 
than 200 genes, including genes responsible for the regulation of cellular 
proliferation, differentiation, apoptosis and angiogenesis (9, 12, 25, 46).  
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Vitamin D and Cancer 
The anti-neoplastic activity of 1,25D is seen in the tumors of the prostate 
(15-17), breast (18) and colon (13, 14) in vitro and in vivo.  The mechanisms 
underlying the antineoplastic activity of 1,25D could be mediated by both 
genomic and non-genomic pathways.  In osteoblasts, cytoplasmic 1,25D 
signaling initiates non-genomic pathways via classic VDR mechanisms.  This 
process includes modulation of the electrical state of the plasma membrane, 
elevation of intracellular calcium and activation of protein kinases (19).  The 
transcriptional and post-transcriptional control of gene expression may be 
mediated by 1,25D (26).  By binding to the nuclear VDR, 1,25D functions as a 
transcription factor and modulates the expression of genes involved in cell cycle 
progression (45).  Tissues express 25-hydroxyvitamin D-1α- hydroxylase and 
produce 1,25D locally.  It is hypothesized that cancer may be prevented by 
controlling genes that regulate cellular proliferation and differentiation (12).  
There is also evidence that cross-talk between non-genomic and genomic 
pathways occurs (19). 
In vitro studies show local 1,25D synthesized in osteoblasts regulates 
proliferation and induces differentiation in normal osteoblasts of human (29, 47), 
rodent (48) and canine (32) origin.  Human osteoblasts responded to exogenous 
1,25D by decreasing their rate of proliferation, and increasing their expression of 
osteocalcin (7, 47), a marker of osteoblast differentiation.  Siggelkow et al. found 
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similar increases in osteocalcin and alkaline phosphatase in osteoblasts 
incubated with 1,25D (49).  
In the presence of exogenous 25D, osteoblasts were shown to undergo 
molecular changes at the transcriptional level, following metabolism of 25D to 
1,25D (7, 25).  Proliferation is inhibited and differentiation induced in normal 
human osteoblasts after treatment with 25D (25).   
 
Growth Inhibitory Effects of 1,25D in Osteosarcoma Cells 
Current literature suggests cancerous cells of bone, including 
osteosarcoma, synthesize 1,25D (25, 46).  Many studies report 1,25D inhibits 
osteosarcoma cell proliferation in a time- and dose-dependent manner (11, 19-
24, 26-28, 50, 51).  Table 1 summarizes the studies demonstrating an 
antiproliferative effect of 1,25D in osteosarcoma. 
The amount of 1,25D required to produce antiproliferative effects in 
cellular models varies.  The majority of studies have found 10nM effective to in 
inhibiting cellular growth.  Employing a range of dosages below 10nM, Ryhanen 
et al. observed 50% inhibition (IC50) of proliferation in MG-63 osteosarcoma cells 
was 120pM or 0.12nM (24).  Dose-response studies are needed to determine the 
effective dosages in various cell lines. 
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TABLE 1. Antiproliferative effects of 1,25D in osteosarcoma cells1 
Study Cells Dose 1,25D Mechanism 
Ryhanen et al. 
200324 MG-63 1pM-100 nM  
G1 arrest, increased 
p27, reduced p21, 
hypophosphorylation of 
Rb protein 
Li et al. 200826 MG-63 0.01-1 nM Not studied 
Finch et al. 
200151 MG-63 
0.01-1000 
nM Not studied 
Barroga et al. 
199950 Canine POS 0.1-10 nM  Not studied 
Tsuchiya et al. 
199321 OST 0.1-1000 nM Not studied 
Witasp et al. 
200522 TE-85 1-50 nM  Not studied 
Zenmyo et al. 
200128 MG-63 1-100 nM  
G1 arrest, p-53 
independent induction of 
p21 (Waf1/Cip1) 
Chattopadhyay 
et al. 200311 MG-63 1-1000 nM Not studied 
Matsumoto et 
al. 199820 MG-63 10 nM  
G1 arrest, induction of 
p21 (Waf1/Cip1), 
decreased activity of Rb 
protein 
Wu et al. 
200719 SaOS-2 10 nM  
G1 arrest, MAPK /AP-
1/p21 pathway activation 
Atkins et al. 
200725 
MG-63, 
SaOS-2, 
HOS, G-292 
10-100 nM Not studied 
Hansen et al. 
200123 
MG-63, 
SaOS-2 100 nM Not studied 
Ryhanen et al. 
199827 MG-63 100 nM  G1 arrest 
Morales et al. 
200434 Rat UMR-106 10 nM G1 arrest
2
 
 
       1Unless otherwise noted (Canine POS, Barroga et al, Rat UMR-106, Morales et al.), all cells    
      are human osteosarcoma cell lines 
       2No inhibition of proliferation was noted in this study 
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Mechanisms Involved in 1,25D Effects on Proliferation  
The mechanisms by which 1,25D regulates proliferation in osteosarcoma 
are not fully understood.  The progression of the cell cycle from the G1 phase to 
the S phase is known to be a critical step in the control of cell proliferation (52).  
Cells that progress into the S phase synthesize new DNA in preparation for cell 
replication while cells resting in G1 may differentiate.  Because the severity of a 
tumor is inversely correlated with the degree of cell differentiation (53), any effect 
of 1,25D to arrest cells in the G1 phase could be an important feature of the 
vitamin. 
Several studies in osteosarcoma cells demonstrate that 1,25D exerts its 
antiproliferative effect by arresting cells in the G1 phase of the cell cycle (20, 24, 
27, 28) giving cells the opportunity to terminally differentiate.  
In these cells, 1,25D may regulate one or more factors critical for the G1/S 
transition in the cell cycle (54).  The main cyclin-dependent kinases (Cdk) 
involved in G1 phase are Cdk2, Cdk4 and Cdk6, and potential mediators in G1 
phase block are the Cdk inhibitors (CKIs), p21 and p27 (7).  Several studies 
show 1,25D binds to the VDR which functions as a transcription factor to 
modulate expression of various genes involved in cell cycle progression (9, 45, 
55, 56).  The specific proteins responsible for the 1,25D mediated G1 arrest are 
not yet known.   
 
12 
 
Differentiation of Osteosarcoma Cells by 1,25D 
Treatment with 1,25D results in the differentiation of osteosarcoma cells to 
mature osteoblasts (29, 20, 21, 23-26, 28, 30, 31). Differentiation studies in 
human osteosarcoma cells report that, 1,25D at concentrations of 10nM-100nM, 
stimulates the expression of several markers of osteoblastic differentiation 
including osteocalcin (21-25, 27, 30, 31), alkaline phosphatase (20, 21, 26, 28, 
30, 31), and incorporation of calcium into the extracellular matrix (25, 29).  Early 
in osteoblastic differentiation, type I collagen is expressed after exposure to 
1,25D (29, 32, 33).  Table 2 summarizes the results of studies of the effects of 
1,25D on markers of osteoblastic differentiation. 
The ability of 1,25D to enhance the expression of these differentiation 
markers in osteosarcoma cells could be an important attribute of the vitamin in 
modulating osteosarcoma.  Osteocalcin secretion and mineralization are 
important late markers of osteoblastic differentiation.  Alkaline phosphatase 
activity and type I collagen production are proportional to the degree of 
osteogenesis (6).  Differentiation of those cells shows a progression away from 
nonspecific proliferation and towards defined lineage-specific growth and 
development.  The results in the in vitro literature suggest that 1,25D promotes 
terminal differentiation of cancerous cells into normally functioning osteoblasts. 
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TABLE 2. Osteogenic markers induced or enhanced in osteosarcoma cells after 
treatment with 1,25D or 25D1 
 
Study Cells Dose 1,25D Markers Induced or Enhanced  
Atkins et al. 
200725 
MG-63, SaOS-2, 
HOS, G-292 
10-100 nM 
1,25D 
10-100 nM 25D 
Mineralization 
Osteocalcin 
Barroga et 
al. 200032 Canine POS 10 nM 
Alkaline Phosphatase 
Osteocalcin 
Type I Collagen 
Hansen et 
al. 200123 MG-63, SaOS-2 100 nM Osteocalcin 
Li et al. 
200826 MG-63 0.01-10 nM Alkaline Phosphatase 
Matsumoto 
et al. 199821 MG-63 10 nM  
Alkaline Phosphatase 
 
Matsumoto 
et al. 199129 MC3T3-E1 0.3  nM 
Alkaline Phosphatase 
Type I Collagen 
Mineralization 
Nozaki et al. 
199933 
Canine POS, 
53C, 53D, 14A 0.1-1000 nM 
Alkaline Phosphatase 
Osteocalcin 
Type I Collagen 
Rao et al. 
200130 SaOS-2 0.1-1000 nM 
Alkaline Phosphatase 
Osteocalcin 
Ryhanen et 
al. 199827 MG-63 0.1-1000 nM Osteocalcin 
Sunita Rao 
et al. 200231 MG-63 1000 nM Osteocalcin 
Tsuchiya et 
al. 199321 OST 0.1-1000 nM 
Alkaline Phosphatase 
Osteocalcin 
Witsap et al. 
200522 Rat UMR-106 1-50 nM Osteocalcin 
Zenmyo et 
al. 200128 MG-63 1-100 nM 
Alkaline Phosphatase 
Osteocalcin 
 
     1Unless otherwise noted, all cell lines are human osteosarcoma lines 
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Apoptosis in Osteosarcoma Cells after Treatment with 1,25D 
Apoptosis generates characteristic morphological and biological changes 
in the cellular life cycle ending in cell death.  Apoptosis is an important factor in 
cell-cycle regulation of all cells (57).  It is an important contributor to growth 
suppression in hyperproliferative states like cancer (35).   
It is hypothesized that the anti-proliferative activity of 1,25D may be 
attributed to 1,25D-induced apoptosis (33, 35).  The vitamin D-modulated G1 
arrest observed in earlier literature (19, 20, 23, 27, 28, 34) is due to an 
antiapoptotic effect (34), an antiproliferative effect (24) or a combination of both.  
In vitro studies report 1,25D is capable of inducing apoptosis as confirmed by 
DNA fragmentation in canine osteosarcoma (33, 35).  The results of studies in 
rodent and human osteosarcoma cells show 1,25D or 25D inhibited (26, 34) or 
had no effect on apoptosis (22, 23), although studies in canine osteosarcoma 
cells were performed at higher dosages (Table 3).  
In the presence of apoptosis-inducing agents, the literature is also 
contradictory:  1,25D is either protective (23, 34, 58) or fails to protect cells from 
death (22).  It is suggested that this discrepancy is due to cell density (cells per 
milliliter or total cells/ml) at initiation of the experiment.  Evidence suggests that at 
high density (100% confluence), the majority of cells are killed by 1,25D, whereas 
at lower density (60-70% confluence), 1,25D exerts anti-apoptotic effects during 
the initial days of culture, followed by cell death upon prolonged cultivation (22). 
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TABLE 3. Summary of research on apoptosis in osteosarcoma cells treated with 
1,25D or 25D1 
 
 Study  OS Cell lines Vitamin D  (1,25D)  Dose 
Induces 
Apoptosis 
Barroga et al. 
199835 Canine POS  1-1000 nM 
Nozaki et al. 
199933 
Canine POS, 53C, 53D, 
14A  0.1-1000 nM  
Inhibits 
Apoptosis 
Li et al. 200826 MG-63  1 nM  
Morales et al. 
200434 Rat UMR-106  10 nM  
Does Not 
Affect 
Apoptosis 
Hansen et al. 
200123 MG-63 and SaOS-2  
1-100nM 
1,25D 
1-100nM 25D 
Witasp et al. 
200522 
Rat UMR-106 and Human 
TE-85  1-50 nM 
 
 
      1Unless otherwise noted, all cell lines are human osteosarcoma lines 
 
Because of the contradictory evidence found in the literature, signaling 
pathways involved in the apoptosis regulatory effects of 1,25D need to be 
identified. A number of markers involved in the process are now known or 
identified. 
The chain of events in apoptosis is highly ordered and includes the 
sequential activation of different members of a family of proteases called 
caspases (59).  Morales et al. demonstrated that caspase-3, 8 and 9 activities 
significantly decreased in osteosarcoma cells after treatment with 10nM 1,25D 
for 2 days (34).  This verifies a major role for 1,25D in their observed 
antiapoptotic effect.  Witasp et al. demonstrated that 1,25D failed to activate 
caspase 3-like enzymes in rat UMR-106 and human TE-85 osteosarcoma lines 
(22). 
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Members of the Bcl-2 protein family have the ability to modify the 
apoptotic pathway by regulating caspase activity.  Bcl-2 and BAX are two 
members of this protein family shown to be involved in apoptosis.  Bcl-2 exerts 
an antiapoptotic effect by inhibition of cytochrome c release, while BAX asserts a 
pro-apoptotic effect by increasing cytochrome c release (60).    
The active form of vitamin D protects normal thyrocytes from undergoing 
apoptosis by up-regulating Bcl-2 expression, an anti-apoptotic protein (61).  
Hansen et al. suggest that up-regulation of Bcl-2 may play a central role in the 
inhibition of apoptosis observed after 1,25D treatment in osteosarcoma (23).  
Morales et al. showed increased expression of Bcl-2 and reduced levels of BAX 
in human osteosarcoma cells after treatment of 10nM 1,25D for 24h (34).  In 
breast cancer cells, 1,25D induces apoptosis resulting from the down-regulation 
of the anti-apoptotic bcl-2 protein (18).  Down-regulation of bcl-2 has yet to be 
illustrated in osteosarcoma cells.  It is obvious 1,25D regulates the bcl-2 family 
proteins.  It is unclear what mechanism ultimately affects cell apoptosis. 
Apoptosis by 1,25D in osteosarcoma cell lines may involve additional signaling 
pathways but these are unknown. 
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The Effects of 25D in Osteosarcoma 
There is little information available in the literature comparing the effects of 
25D versus 1,25D treatment in osteosarcoma cells.  In 2002, Gurlek et al. found 
osteoblast-like cells respond transcriptionally to physiological concentrations 
(100nM) of 25D by conversion of 25D to 1,25D (7).  Atkins et al. further 
investigated the effects of 25D on cellular processes in a variety of osteosarcoma 
cell lines. Consistent with 25D’s conversion to 1,25D, exposure to 25D at 100nM 
inhibited cellular growth to the same extent as 1,25D at a pharmacological level 
(1nM).  Messenger RNA expression of osteocalcin and mineralization increased 
(25). 
 
Gaps in Current Research and Targets for Future Directions  
In some osteosarcoma cells 1,25D exerts an antiproliferative effect and is 
a potent prodifferentiation agent.  In human osteosarcoma cells, 1,25D inhibits 
growth in a time- and dose-dependent manner and stimulates the expression of 
osteocalcin and alkaline phosphatase and mineralization in human osteosarcoma 
cells.   
There remain significant unknowns and contradictions in current literature 
on 1,25D and osteosarcoma.  The effective dosages of 1,25D in osteosarcoma 
cells are not well summarized and mechanisms involved in these actions remain 
unclear.  The research on the role of 1,25D in modulating apoptosis of cancer 
cells is contradictory at present. The potential of 25D to metabolize and exhibit 
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similar effects to 1,25D is not adequately studied and merits further research.  
The current study examines the dose response of 1,25D and 25D in modulating 
proliferation, differentiation and apoptosis in a comprehensive manner. 
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CHAPTER 3 METHODS 
 
The purpose of this study was to investigate the dose response of vitamin 
D on the processes of cellular differentiation, proliferation and apoptosis in 
human osteosarcoma cell lines, SaOS-2 and 143B.  Concentrations of 1-1000nM 
1,25D and 25D were tested versus ethanol controls in osteosarcoma cells.  A 
variety of assays, immunocytochemical and staining techniques were used to 
examine changes in cell differentiation, proliferation and apoptosis in these cells. 
 
Setting 
All activities took place at the University of Kansas Medical Center (KU 
Medical Center) in the Bone Research Lab, Department of Pathology and 
Laboratory Medicine and the Department of Dietetics and Nutrition. 
 
Ethics 
This study qualifies as exempt from Human Subjects Approval as the cell 
lines used are considered secondary data, or data collected prior to the research 
for a purpose other than the proposed research.  The cells used in this study are 
publicly available and contain no identifying markers. 
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Materials 
Cell Culture 
Human osteosarcoma cell lines, SaOS-2 and 143B (American Type 
Culture Collection; Manassas, VA) were used in this study.  SaOS-2 and 143B 
cells are tumorigenic with an osteoblast-like phenotype.  SaOS-2 is p53 null and 
metastatic (62), while 143B is ras gene transformed and highly metastatic (66). 
Cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 5% Penicillin/Streptomycin, 10% fetal bovine serum (FBS), 
5% non-essential amino acids and 5% glutamine.  Cells were maintained in 
standard conditions at 37°C in a humidified (95% air: 5% CO2) incubator.  Culture 
medium was changed 3 times per week.  
 
Agents 
Osteosarcoma cells were cultured in the presence of 1,25D or 25D at 
concentrations of 1nM, 10nM, 100nM or 1000nM or appropriate ethanol controls.  
Vitamin D stocks (1,25D and 25D) were purchased from BIOMOL Research 
Laboratories Inc. (Plymouth Meeting, PA).  Stock solutions were prepared in 
ethanol and frozen at -20⁰C until use. 
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Data Collection and Procedures 
Cell Counting and Viability 
Thirty thousand (3 x 104) cells were seeded in 6-well plates.  Cells were 
trypsinized and quantified with a Bright-Line Hemocytometer (Sigma-Aldrich, St 
Louis, MO) using trypan blue exclusion assay after 96h of proliferation.  Trypan 
blue dye is taken up by non-viable cells whose cell membrane is disrupted.  
Fifty microliter cell suspension was removed and diluted 1:10 with 0.4% 
Trypan blue. Suspension was mixed thoroughly and incubated at room 
temperature for 5 minutes.  Approximately 1 µl of suspension was placed in a 
hemocytometer and the number of viable (unstained) and nonviable (stained) 
cells in the corner quadrants were counted (n=3).  
The average number of cells in the four quadrants (N) was determined 
and the cells per ml were determined using the formula: 
Cells per ml= N (average number of cells) x 2500 x 10 (dilution factor) 
 
 
Cell Proliferation MTS –based Assay 
Cell proliferation and viability was determined using the Cell Titer 96® 
AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI; Cat# 
TB245).  The MTS cell proliferation assay is a colorimetric method to identify 
viable cells. Metabolism in viable cells produces "reducing equivalents" such as 
NADH or NADPH. These reducing compounds pass the electrons to an 
intermediate electron transfer reagent.  This reagent reduces the tetrazolium 
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product, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS), into an aqueous, soluble formazan product. 
At death, cells rapidly lose the ability to reduce tetrazolium products. The 
production of the purple formazan product is proportional to the number of viable 
cells in culture. 
Eight thousand cells (8 x 103) per well were seeded in 96-well plates. Cell 
proliferation was measured after 96h according to manufacturer’s instructions.  
Plates were read on a microplate reader at 450nm instead of 490nm due to filter 
availability.  The absorbance spectrum of the formazan product shows an 
absorbance maximum at 490nm but data can be recorded at wavelengths 
between 450-540nm. 
 
Ki67 Immunocytochemistry 
 Thirty thousand cells (3 x 104) were seeded in 6-well plates.  After 96h, 
cells were washed 1X with Hank’s Balanced Saline Solution (HBSS) and fixed at 
room temperature with 4% paraformaldehyde for 30 minutes.  Cells were washed 
with Tris-buffered saline – Tween, scraped into centrifuge tubes, and centrifuged 
for 5 minutes.  The cell pellet was embedded into a paraffin block.  Paraffin 
blocks were sectioned at 4 µm, mounted on Superfrost + slides and baked in a 
65°C oven for one hour.  The sections were processed fo r Ki67 
immunocytochemistry on a Dakocytomation Autostainer according to the 
manufacturer’s protocol (Dakocytomation, Carpinteria, CA).  Antibody to Ki67 
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(clone MIB-1) was purchased from Dakocytomation, and Ki-67 expression was 
detected using peroxidase conjugated secondary antibody and a peroxidase 
substrate (3, 5-diaminobenzidine). 
 
Flow Cytometry Analysis 
Three hundred thousand cells (3 x 105) were plated in T-25 flasks.  Cell 
culture medium was removed at subconfluence (96-120h); cells were trypsinized, 
resuspended in HBSS and stored in ethanol at 4°C unti l further use.  The day of 
flow cytometry analysis, cells (≥ 106) were pelleted and resuspended in 
Propidium Iodide (50 µg/ml).  Cells were incubated in the dark at 37°C for 45 min 
after the addition of 100 µl of 1mg/ml RNase.  Samples were analyzed on BD 
LSR II equipment in the Flow Cytometry Core Laboratory at KU Medical Center 
(Department of Microbiology, Molecular Genetics and Immunology).  
 
Alkaline Phosphatase Enzyme Activity 
Para-Nitrophenyl Phosphate (pNPP) was used as a substrate to quantify 
alkaline phosphatase (ALP) activity in cell cultures using colorimetric assay. 
Upon dephosphorylation by phosphate, pNPP turns yellow and is detected on a 
microplate reader. 
Eight thousand cells (8 x 103) per well were plated in 24-well plates. Cells 
were maintained in a differentiating medium containing ascorbic acid (50 µg /ml) 
for 10-12 days.  Cells were cultured in serum-free media for 48h.  Cell lysate was 
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collected and alkaline phosphatase (ALP) activity in cell cultures was determined 
using colorimetric assay (AnaSpec, Inc. San Jose, CA; Cat#71230). The 
manufacturer’s protocol was followed except in the detection step, 10 µl 
standards and samples were used per well instead of 50 µl.  The change in 
protocol was made to avoid saturation of the substrate early after addition. 
 
Osteocalcin Enzyme Immunoassay (ELISA) 
  The human osteocalcin enzyme immunoassay (ELISA) is an analytical 
method using enzyme-linked antibodies as reagents to quantitate osteocalcin 
secretion on a microtiter plate. Bound enzyme labeled antibody is measured 
through a chromogenic reaction. The amount of substrate turnover is determined 
colorimetrically by measuring the absorbance which is proportional to osteocalcin 
concentration.  
 Eight thousand cells (8 x 103) per well were plated in 24-well plates. Cells 
were maintained in a differentiating medium containing ascorbic acid (50 µg /ml).  
After 10-12 days, cells were maintained in serum-free media for 48h.  Cell lysate 
was collected and secretion of osteocalcin was determined by enzyme-linked 
immunoassay (ELISA; Invitrogen, Inc. Camarillo, CA; Cat#KAQ1381) according 
to manufacturer’s protocol.  Osteocalcin in each sample was determined from the 
standard curve. 
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Osteocalcin Immunocytochemistry 
 Eight thousand (143B) or 16,000 (SaOS-2) cells were seeded in chamber 
slides with 700 µL medium per well.  Cells adhered overnight and ascorbic acid 
(50 µg /ml) was added the following day.  Beta glycerophosphate (5mM) was 
added upon confluence and cells grew an additional 5 days.  After 14 days, cells 
were washed with HBSS and fixed with paraformaldehyde (4%).  Cells were 
washed twice with phosphate-buffered saline (PBS).  Cells were treated with 0.3 
% Triton X-100 in PBS for 15 minutes.  The permeabilized cells were washed 
three times with PBS followed by incubating with 0.3 % H2O2 for 15 minutes to 
block endogenous peroxidase activity.  Cells were washed with PBS prior to 
incubating with 1.5 % blocking serum for 1h (to reduce non-specific binding of 
primary antibody), followed by a 3h incubation with primary antibody.  Polyclonal 
goat anti-human osteocalcin antibody was purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA) and osteocalcin immunocytochemistry was 
performed according to the manufacturer’s instructions.  
 
In vitro Mineralization 
Staining by the von-Kossa method is used for demonstrating calcium or 
calcium salt deposits. Cells are treated with silver nitrate solution.  The calcium is 
reduced by UV light, replaced with silver deposits. The bone mineral is blackened 
by the deposition of silver and the osteoid is counterstained with Fast Red dye 
(Sigma-Aldrich, St Louis, MO). 
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Eight thousand (143B) or 16,000 (SaOS-2) cells were seeded in chamber 
slides with 700 µL medium per well.  Cells adhered overnight and ascorbic acid 
(50 µg /ml) was added the following day.  Beta glycerophosphate (5mM) was 
added upon confluence and cells grew an additional 5 days.  After 14 days, cells 
were washed with HBSS and fixed with paraformaldehyde (4%). Cells were 
washed with PBS twice.  Mineralization through incorporation of calcium into the 
extracellular matrix was determined by von-Kossa staining per standard protocol 
(63) with minor adaptations. 
Standard protocol changes included: after adding 50% AgNO3 dropwise to 
each specimen, slides were incubated at room temperature for 10 minutes. The 
unbound AgNO3 was removed by washing the slides twice with distilled H2O. 
Slides were then incubated under UV light for 60 minutes.  The original protocol 
was changed to avoid non-specific binding of silver nitrate. 
 
Apoptosis Detection Using Terminal Deoxynucleotide Transferase dUTP Nick 
End Labeling (TUNEL)  
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end 
labeling (TUNEL) is a technique for detection of apoptotic cells.  Fragmentation 
of genomic DNA during apoptosis generates strand breaks, which can be 
identified by labeling free 3’ OH ends with modified nucleotides in an enzymatic 
reaction.  
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Cells are treated to produce membrane permeability to the reagents and 
enzymes necessary to label the DNA fragments. After cellular uptake of the 
reagents, the enzyme TACS TdT catalyzes the addition of labeled bromolated 
deoxyuridine triphosphate nucleotides (Br-dUTP) to 3′ OH ends of the multimers. 
Eight thousand (143B) or 16,000 (SaOS-2) cells were plated in chamber 
slides.  Cell culture medium was removed after 15 days and the cells were fixed 
with paraformaldehyde (4%).  Detection and quantification of apoptosis was 
determined by TUNEL at single cell level.  Fragmentation was identified by 
labeling free 3’-OH terminal with modified nucleotides in an enzymatic reaction.  
Apoptotic cells were stained using the APO-BRDU kit (Phoenix Flow Systems, 
Inc. San Diego, CA; Cat# AH1001). Manufacturer instructions were followed 
apart from the Detection Step, where slides were incubated in DAB solution 
(DAB, H2O2\ Urea in tap H2O) for 30 minutes instead of 15 minutes.  This step 
was modified to increase contrast in staining. 
 
Analysis of Data 
Excel software (Microsoft Corp., Redmond, WA, USA) was used for all 
statistical analysis.  Means, standard deviations and standard error of the mean 
were calculated for all data.  Paired Student’s t-Tests were used to analyze 
differences in experimental and control data.  A p value <0.05 was considered 
statistically significant. 
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CHAPTER 4 RESULTS 
 
The objectives of the current study were to determine the dose-response 
and identify the effects of vitamin D (25D and 1,25D) on cellular processes in 
osteosarcoma cells.  The effects of 25D and 1,25D (1-1000nM) on proliferation, 
differentiation and apoptosis in human osteosarcoma cell lines SaOS-2 and 143B 
were examined.   
The human osteosarcoma cell lines SaOS-2 and 143B were used in this 
study (Figure 2).  Both lines are tumorigenic.  The source of the SaOS-2 cell line 
is an 11-year-old Caucasian girl (64).  It is p53 null and metastatic (62).  SaOS-2 
cells have a high proliferative capacity and are known to possess high affinity 
receptors for 1,25D (65).  The 143B cell line is a Ki-ras oncogene transformation 
of the HOS osteosarcoma cell line (66) and is highly metastatic.   
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FIGURE 2. (A-B) Phase-contrast photomicrographs of (A) SaOS-2 and (B) 143B 
cells at confluence in culture.  (C-D) Photomicrographs showing Hematoxylin 
Staining of (C) SaOS-2 and (D) 143B cells (Bar= 50 microns).  
 
Cellular Proliferation 
 In order to investigate the effects of 1,25D and 25D on proliferation of 
osteosarcoma cells, the cells were cultured for 4 days in the presence of different 
concentrations of 1,25D or 25D. 
 
Cell Proliferation MTS –based Assay 
Proliferation was increased significantly (p value < 0.05; Student’s t-Test) 
in 143B cells exposed to 1000nM 25D versus control.  At other concentrations, 
neither 1,25D nor 25D had any effect on proliferation.  Neither 1,25D nor 25D 
had any significant effects on proliferation in SaOS-2 cells (Figure 3).  
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(A) 
 
(B) 
 
FIGURE 3. Effects of 1,25D and 25D on cell proliferation in (A) 143B and (B) 
SaOS-2 cells.  Cells were cultured in 96-well plates and proliferation measured 
by MTS-based assay after 96h.  Each data point represents the mean ± SEM 
(n=6). (*Statistical significance, p value < 0.05; Student’s t-Test) 
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Ki67 Immunocytochemistry 
 Ki67 (a marker of cellular proliferation) immunocytochemistry results 
mirrored those of MTS-based assay, with little or no effect in proliferation 
observed in SaOS-2 or 143B cells after treatment with 1,25D or 25D (Figure 4). 
 
 
FIGURE 4. Photomicrographs of Ki67 immunostaining (a proliferation marker) 
after 96h of incubation: (Top Row) SaOS-2 control, SaOS-2 100nM 25D and 
SaOS-2 100nM 1,25D (Base Row) 143B control, 143B 100nM 25D and 143B 
100nM 1,25D.  Brown Peroxidase staining indicates Ki67 expression.  Arrows 
indicate an actively dividing cell where Ki67 is maximal (Bar= 50 microns). 
 
Cell Cycle Analysis 
In SaOS-2 cells treated with 25D at 1000nM, cell cycle analysis revealed a 
significant increase (p value < 0.05; Student’s t-Test) in the percentage of cells in 
the G2/M phase.  There were no significant effects on cell cycle distribution in 
143B cells with 25D or 1,25D treatment. 
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(A) 
 
(B) 
 
FIGURE 5. Effects of 1,25D and 25D on cell cycle distribution as analyzed by 
flow cytometry in (A) SaOS-2 cells and (B) 143B cells.  Cells were cultured in T-
25 flasks and cell cycle distribution was analyzed at subconfluence (96-120h).  
All data points are means ± SEM (n=3). (*Statistical significance, p value <0.05; 
Student’s t-Test) 
* 
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Cellular Differentiation 
A series of experiments measuring markers of osteoblastic differentiation 
were performed to analyze the response of SaOS-2 and 143B cells to 25D and 
1,25D. 
 
Alkaline Phosphatase Enzyme Activity 
Alkaline phosphatase (ALP), an early marker of osteoblastic 
differentiation, activity was measured via colorimetric assay.  In 143B cells 
treated with 1,25D, ALP activity was significantly increased dose-dependently (p 
< 0.05) from 100nM versus control.  In SaOS-2 cells, neither 1,25D nor 25 D 
significantly modified ALP activity versus control (Figure 6).  
 
Osteocalcin Secretion 
 Osteocalcin (a late marker of osteoblastic differentiation) secretion was 
measured using ELISA and immunocytochemistry.  Neither technique was able 
to adequately detect osteocalcin secretion in either SaOS-2 nor 143B cells (data 
not shown).  The ELISA technique was successful in recombinant protein 
osteocalcin (not native) based on the standard curve (Figure 7).  It is unclear 
whether a) osteocalcin expression (native form) was out of the detectable range 
in SaOS-2 and 143B cells or b) SaOS-2 and 143B cancer cells do not express 
osteocalcin in vitro.  Currently experiments are ongoing to measure OCN mRNA 
expression in SaOS-2 and 143B by real time PCR. 
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(A) 
 
(B) 
 
FIGURE 6. Effects of 1,25D and 25D on osteogenic differentiation in (A) 143B 
cells and (B) SaOS-2 cells.  Cells were cultured in 24-well plates in a 
differentiating medium for 12-14 days.  Para-Nitrophenyl Phosphate (pNPP) was 
used to quantify ALP activity in cell cultures.  All data points are means ± SEM. 
(*Statistical significance, p< 0.05; Student’s t-Test) 
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FIGURE 7. Osteocalcin standard curve as determined by ELISA (generated from 
0, 1.9, 3.2, 8.5 and 23 ng/ml standards). 
 
 
FIGURE 8. Slide showing von-Kossa staining of mineralization nodules in SaOS-
2 cells treated with 1000nM 1,25D.  Cells were plated in chamber slides and 
incubated for 12 days in differentiating medium and 1,25D or 25D.  Black staining 
indicates mineralization through incorporation of calcium into the extracellular 
matrix (Bar= 500 microns).  
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(A) 
 
(B) 
 
FIGURE 9. Slides showing von-Kossa staining of (A) SaOS-2 and (B) 143B cells.  
Cells were plated in chamber slides and incubated for 12 days in differentiating 
medium and indicated concentrations of 1,25D or 25D.  Black staining indicates 
mineralization through incorporation of calcium into the extracellular matrix (Bar= 
500 microns). 
 
Apoptosis 
Both 25D and 1,25D had a limited effect on the process of apoptosis in 
SaOS-2 and 143B cells (Figure 10) as evidenced by TUNEL staining.  A 
significant induction of DNA fragmentation (p value < 0.05; Student’s t-Test) was 
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observed with 25D at 1000nM in both cell lines but no other significant changes 
were observed after 15 days of treatment (Figure 11). 
 
(A)   
 
(B) 
 
FIGURE 10. TUNEL staining in (A) SaOS-2 and (B) 143B cells.  Cells were 
plated in chamber slides and incubated with indicated 1,25D or 25D 
concentrations for 15 days. Peroxidase staining indicates an apoptotic cell (Bar= 
50 microns).
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(A) 
 
(B) 
 
FIGURE 11. Semiquantitative analysis of apoptotic cells after treatment with 
1,25D or 25D in (A) SaOS-2 and (B) 143B cells.  Cells were cultured on chamber 
slides and apoptotic cells were identified via TUNEL staining after 15 days. Five 
sites on each slide were selected at random and apoptotic cells were counted at 
40X using a scaled standard.  All data points are means ± SEM. (N=5; *Statistical 
significance, p value <0.05; Student’s t-Test) 
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Differences in Control Cells 
Biological differences between SaOS-2 versus 143B control cells were 
observed.  Cell cycle analysis revealed significantly more (p< 0.05; Student’s t-
Test) SaOS-2 control cells in G0/G1 than 143B and significantly fewer (p< 0.05; 
Student’s t-Test) SaOS-2 cells in synthesis phase than 143B.  There was a 2-fold 
increase in SaOS-2 control cells in G2/M than 143B (Table 4; Figure 12).  
SaOS-2 control cells had alkaline phosphatase activity levels significantly higher 
(p<0.05; Student’s t-Test) than 143B cells (Table 5). 
 
TABLE 4. Cell cycle distribution of SaOS-2 versus 143B control cells1 
Cell Cycle 
Phase 
SaOS-2 Control Cells 
(%) 
143B Control Cells 
(%) P-value 
Sub G0          9.42 ± 3.042        3.78 ± 1.51   0.2167 
G0/G1        67.23 ± 5.45      55.27 ± 4.89   0.0181* 
S        15.63 ± 2.74      30.48 ± 1.36   0.0029* 
G2/M   5.3 ± 1.37        11.7 ± 3.36   0.1458 
 
1Cells were cultured in T-25 flasks and cell cycle distribution was analyzed at 
subconfluence. 
2Mean percentage ± SEM (all such values). 
*Statistical significance, p value <0.05; Student’s t-Test. 
 
TABLE 5. ALP enzyme activity in control cells1 
 
 Mean SEM P-value 
SaOS-2 Control Cells 2439.51 262.44  
143B Control Cells   198.19   36.54 0.0115* 
 
1ALP enzyme activity per milligram protein in SaOS-2 versus 143B control cells.  Cells were 
cultured in 24-well plates in a differentiating medium for 12-14 days.  Para-Nitrophenyl 
Phosphate (pNPP) was used to quantify alkaline phosphatase activity in cell cultures.  
*Statistical significance, p value < 0.05; Student’s t-Test 
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FIGURE 12. (A) Cell cycle distribution as analyzed by flow cytometry in SaOS-2 
versus 143B control cells.  (B-C) Flow cytometry histograms of (B) SaOS-2 and 
(C) 143B cells.  Cells were cultured in T-25 flasks and cell cycle distribution was 
analyzed at subconfluence (96-120h).  All data points are means ± SEM 
(*Statistical significance, p value <0.05; Student’s t-Test). 
 
 
 
(A) 
(B) (C) 
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CHAPTER 5 DISCUSSION 
 
Cellular Proliferation 
Treatment with 1,25D did not affect proliferation of either cell line after 96 
hours of incubation.  Proliferation was increased significantly versus control in 
143B cells exposed to 25D at 1000nM (MTS assay).  Ki67, a marker of cellular 
proliferation that is maximal in an actively dividing cell, was detected in this study 
via immunocytochemistry.  Little differences were seen in Ki67 expression 
between control and treatment cells in either cell line. 
The findings showed neither 25D nor 1,25D inhibit cellular proliferation. 
This finding contradicts the study hypothesis as well as other research.  It was 
expected from previous investigations (11, 19, 20, 22-28) that 25D and 1,25D at 
concentrations as low as 10nM would inhibit cell growth in a dose dependent 
manner.  The lack of effect on cellular proliferation by 1,25D has been observed 
in rat osteosarcoma cells (34).  SaOS-2 was previously shown to possess high 
affinity receptors for 1,25D (23, 65), verifying the cells have the ability to respond 
to 1,25D.  Higher concentrations of 1,25D or 25D may be needed to elicit a 
response from the cells or a different time period may be necessary to inhibit 
proliferation.  
The 96-hour incubation was not an appropriate time period to observe 
1,25D-mediated proliferation changes in this study.  In human myeloblastic 
leukemic (HL60) cells, several studies reported treatment with 1,25D causes an 
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initial increase in proliferation followed by an inhibition (61, 67-69).  A similar 
increase in proliferation by 25D was observed in 143B cells in this study.  Other 
incubation times need to be observed to obtain a comprehensive depiction of 
proliferation in these cells. 
VDR status and expression of genes and/or proteins important to tumor 
progression may be different in these cells based on the failure of 1,25D to inhibit 
proliferation.  The differences in response by SaOS-2 and 143B signify a genetic 
variation between the lines and a further need for testing of VDR status in both 
cell lines.  VDR status is important as a reduction in proliferation of SaOS-2 cells 
has only been observed in the presence of a functional VDR (19).  There is a 
positive correlation between numbers of 1,25D receptors and the anti-tumor or 
differentiating effects (19). 
Inhibition of cell proliferation is tightly linked to mechanisms that regulate 
cell cycle progression.  The antiproliferative actions of 1,25D were attributed to 
cell cycle perturbation (19, 24, 28), namely cell cycle arrest in the G1 phase (19, 
20, 24, 28).  Cell cycle analysis was performed to investigate potential 1,25D or 
25D-mediated cell cycle changes.  Inhibition of proliferation was not observed, 
and only minor changes in cell cycle distribution in either osteosarcoma cell line 
was detected.  
Cell cycle analysis varies with different incubation times. Ryhanen et al. 
reported 1,25D-mediated effects on regulatory cell cycle proteins taking place 
between 24 and 72h (24).  The cell cycle analyses presented in this study were 
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tested after 96h incubation.  Cell cycle changes might be sustained with transient 
1,25D treatment from 24 to 96h, but it cannot be assumed.  Wu et al. found that 
sustained but not transient 1,25D treatment caused a significant reduction of 
SaOS-2 cell proliferation (19).  Both 1,25D and 25D need to be tested in higher 
concentration or added daily to observe cell cycle effects.  
Other studies required serum-reduced medium to observe a persuasive 
reduction in cell proliferation (22, 28).  As little as 0.1% FBS was successfully 
used in osteosarcoma proliferation studies (28).  Ten percent FBS was utilized 
providing proteins that bind 1,25D or 25D, such as albumin and the vitamin D 
binding protein (25).  Recent literature suggests 1,25D binds to serum proteins in 
the media and is not transported into the cell (58).  The use of serum-reduced 
media will enhance the bioavailability of 25D and1,25D in culture and should be 
tested in future studies. 
 
Cellular Differentiation 
Osteosarcoma results from the malignant transformation of osteoblasts 
(21).  In the differentiation of osteoblasts, a specific order of gene expression 
exists.  The markers of osteoblastic cells—ALP, mineralization and osteocalcin—
were examined to determine degree of differentiation of osteoblast-like cells, 
SaOS-2 and 143B. 
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Alkaline Phosphatase Enzyme Activity 
ALP plays a significant role in facilitating bone mineralization and is used 
as an early marker of osteoblast differentiation (32).  In this study, 1,25D at 
higher concentrations significantly increased ALP activity in 143B cells but not in 
SaOS-2 cells.  The stimulation of ALP activity by 1,25D at higher concentration in 
143B cells supports the study hypothesis and conforms with research in other 
human osteosarcoma cells (20, 21, 26, 28-30, 47).  A similar increase in ALP 
activity with 1,25D treatment in SaOS-2 cells has been previously observed (30) 
and this discrepancy needs further explanation.  
Treatment with 1,25D may target increases in ALP activity in less 
differentiated cells.  In this case, SaOS-2 cells are innately more differentiated 
than 143B cells.  SaOS-2 cells had 12-fold higher baseline ALP activity levels 
than 143B cells in control cells (Table 4), as well as an elevated expression of 
other osteoblastic markers found in literature (23, 25, 62). 
ALP expression has differed in vitro and in vivo.  A study by Dass et al. 
showed ALP expression in culture in SaOS-2 cells increased by 48% in primary 
tumors and further increase140% in metastatic lesions in the lungs as 
determined by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).  In 
the same study, 143B did not express ALP in culture, but expressed ALP to the 
same level as SaOS-2 in the primary lesions (62). 
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Osteocalcin 
Osteocalcin is one of the most abundant osteoblast-specific proteins 
whose levels post-proliferatively upregulate during extracellular matrix 
mineralization (70).  Osteocalcin was not detected in either of the cell lines using 
ELISA nor immunocytochemistry.  This was due to either: a) a technical issue in 
antibody binding or detection of the protein, or b) a lack of expression in the cells.  
Technically, different dilutions of cell suspension were tested (1:1 – 1:100) using 
the ELISA method. Incubation periods with antibodies were assessed from 2 
hours to overnight but without success. 
It was expected that osteocalcin would be expressed in SaOS-2 control 
cells as demonstrated in previous literature (62).  A 1,25D responsive element 
was identified in the promoter region of the human osteocalcin gene (71) and 
both 1,25D (26-30, 33-35) and 25D (25) were shown to augment osteocalcin 
secretion or expression in osteosarcoma cell lines. It was cited that human 
osteoblasts do not express osteocalcin in a stringent maturation stage-dependent 
fashion (47).  Timing and stage of cell growth play a factor in results and vary 
between cell lines.  Dass and colleagues found no expression of osteocalcin in 
SaOS-2 or 143B cells in culture, but found it was readily detectable in both 
SaOS-2 primary and secondary tumors (62).  Those studies showing differential 
expression of osteocalcin between in vitro and in vivo environment suggest that 
the expression and stability of this protein are influenced by the tumor 
microenvironment. 
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 Ryhanen et al. found maximum responses in osteocalcin mRNA levels 
were reached within 24h (27).  The osteocalcin ELISA and immunocytochemistry 
assessments of protein levels in this study were completed after 15 days of 
incubation.  Osteocalcin may be expressed transcriptionally but not post-
transcriptionally in these cells.  Based on the reported issues, osteocalcin mRNA 
is currently being tested at various time points via RT-PCR for further 
investigation. 
 
In Vitro Mineralization  
Both SaOS-2 and 143B cells formed multiple mineralization nodules in 
culture after 12 days, and nodules appeared to increase at higher concentrations 
of both 25D and 1,25D as examined by von-Kossa staining.  The numbers of 
nodules were not quantified because of their small size, and were not proven 
statistically significant.  Current in vitro mineralization experiments are focused 
on increasing the extent of mineralization time period to 21 days, allowing the 
nodules to attain a reasonable size to be readily quantified. 
These results are similar to the results of others (25, 29) showing that both 
25D (100nM) and 1,25D (0.3-10nM) can induce mineralization of osteosarcoma 
cells by incorporation of calcium into the extracellular matrix. Collectively, the 
results suggest that both 25D and 1,25D at higher concentration (100-1000nM) 
have a direct effect on the bone mineralization process of these cells and 
regulate the osteogenic function of these cells.  The ability of 25D to effectively 
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promote mineralization in vitro implies that serum 25D regulates this activity in 
vivo. 
In the present study, both 25D and 1,25D act as a differentiation agents in 
SaOS-2 and 143B cells.  Both 25D and 1,25D help promote differentiation 
towards a functionally mature osteoblastic bone cell as suggested by 
experiments in markers of osteoblastic differentiation. Tumor severity is inversely 
correlated with the degree of cell differentiation (53).  These findings show that 
25D and 1,25D can decrease the severity of osteosarcoma in vitro.  Both 1,25D 
and 25D appear more effective in promoting change in the less differentiated cell 
line, 143B, than SaOS-2. 
The discrepancies between cell lines, 1,25D concentrations and other 
literature cannot be simply explained.  Transcriptional activation by 1,25D is 
complex, involving heterodimerization of retinoid X-receptors (RXR) and VDR, 
and multiple co-activator proteins (72).  This complexity accounts for many of its 
gene- and stage- specific effects.  The apparent differences in the sensitivity to 
1,25D involve variations in VDR status, the phenotypic maturation of the cell or 
the structure-function relationship between 25D and 1,25D used. 
 
Apoptosis 
A biochemical feature of apoptosis is the fragmentation of genomic DNA.  
Using TUNEL staining to label fragmented DNA, it was demonstrated that 1,25D 
and 25D had limited effects on apoptosis in SaOS-2 and 143B cells.  A 
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significant induction of DNA fragmentation was observed with 25D at 1000nM in 
both cell lines but no other significant changes were observed. 
The current study demonstrates that 1,25D alone does not affect 
apoptosis. This finding is in agreement with the results of several studies (22, 23, 
34), suggesting that programmed cell death may not contribute to the anticancer 
properties of 1,25D, and that mechanisms of antineoplastic effects lie elsewhere.  
Semi-quantification of TUNEL staining revealed 25D can indeed enhance 
apoptosis in human osteosarcoma cell lines.  Apoptosis induction by 25D at high 
concentration (1000nM) in SaOS-2 and 143B cells is not reported elsewhere.  
The active form of vitamin D affects numerous signaling pathways and 1,25D-
induced cytotoxicity differs among cell types.  Investigation of the signaling 
pathways regulated by 1,25D should be examined, as previous research found a 
variety of pathways and proteins—Bcl-2, BAX and caspases—involved in 
apoptosis.   
 
Differences in Control Cells 
Both human osteosarcoma lines used in this study are tumorigenic, but 
not isogenic.  Biological differences between SaOS-2 and 143B control cells 
were observed.  SaOS-2 cells are intrinsically more differentiated than 143B as 
evidenced by significantly enhanced ALP specific activity in control cells.  
Significantly more 143B cells than SaOS-2 cells in the synthesis phase of the cell 
cycle suggest a higher rate of replication in these cells. 
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These inherent differences in the biology of SaOS-2 and 143B 
osteosarcoma cells modulate response to 1,25D.  There may be several 
underlying reasons.  First, the switch to differentiation mode is not rapid for some 
cells but rather an initial increase in proliferation is observed, as seen in HL60 
(61, 67, 68) or U937 (69) cells differentiating in response to 1,25D.  
Secondly, the inherent differences in the biology of the two cell lines—the 
absence of expression of retinoblastoma protein in the SaOS-2 cell line, and ras 
gene transformation in the 143B cell line—may alter the cells’ response to 1,25D.  
Li et al. indicate species differences should be taken into account in studies of 
1,25D effects (26).  Because these lines are not isogenic, lack of genetic 
similarity could be a potential problem in the response to 1,25D or 25D. 
VDR status as well as expression of proteins important in tumor 
progression in these two cell lines is not known.  Investigation in the differences 
in VDR status through immunocytochemistry and with RT-PCR may be 
necessary to quantify these values for a useful conclusion.  VDR content and 
intracellular levels of vitamin D metabolites are the main determinants of the 
magnitude of the response to 1,25D therapy by a target tissue (51). 
 
Limitations 
An obvious limitation of this study is the in vitro methodology.  This study 
overlooks the complexity of the in vivo tumor environment where there is 
interplay between different cell types and signaling pathways which could have 
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influence on tumor growth and progression.  In vitro studies are important for 
gathering preliminary data on the effect of 1,25D on osteosarcoma cell lines and 
can provide the foundation for future in vivo and translational studies.  A second 
limitation of the study is the small sample and lack of power. This study serves as 
a pilot for future study and the results need to be reproduced on a larger scale 
with adequate statistical power.  
Limitations in methodology were incurred during the duration of study. 
Other studies have required serum-reduced medium to observe 1,25D or 25D-
mediated effects (22, 28).  Ten percent FBS was used in this study, while as little 
at 0.1% FBS has been successfully used in other osteosarcoma proliferation 
studies (28).  Ten percent FBS may provide proteins that can bind 1,25D or 25D 
such as vitamin D binding protein and albumin (25).  Serum reduced media 
should be tested in future studies. 
In apoptosis experiments, TUNEL alone was used to examine apoptotic 
cells in culture.  In reality, other methods of identifying apoptotic cells—
Transmission Electron Microscopy (TEM) or Annexin-V staining—should be used 
to confirm TUNEL results, examine the characteristic morphological features of 
apoptosis and exclude necrotic cells.  
 
Implications 
It is important to further clarify and summarize the effects of 25D and 
1,25D on cellular processes in human osteosarcoma cells.  Other potential 
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therapeutic targets for osteosarcoma need to be explored in detail.  The 
observation that 1,25D at higher concentration increases ALP activity in 143B 
cells and promotes mineralization in SaOS-2 and 143B cells suggests that 1,25D 
and 25D may act as a differentiation agents in these cells.  These studies should 
be repeated and quantified for statistical power.  The potential use of 25D 
therapeutically as a pro-apoptotic agent in osteosarcoma is uncertain.  The role 
of 25D in apoptosis of osteosarcoma cells exhibited in this study needs to be 
confirmed and clarified, including investigations into the pathways involved.  
Knowledge gained from this study provides a better insight into 
understanding the mechanism of action of 1,25D on osteosarcoma cells and may 
provide the framework for future in vivo studies.  Given the prevalence of 
osteosarcoma in children, adolescents and canines, a better understanding of 
the underlying mechanisms of disease are important for identification of 
biomarkers that may provide targets for devising novel therapies.  The ability of 
1,25D or 25D to promote normal osteogenic differentiation and affect apoptosis 
in osteosarcoma cells may be useful in the future to suppress the aggressive and 
malignant properties of osteosarcoma.  
 
The research here has led to the presentation of results at the 2008 
American Institute of Cancer Research’s (AICR) Annual Conference on Food, 
Nutrition, Physical Activity and Cancer (Abstract- Appendix A).  A manuscript is 
also in preparation. 
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Conclusions 
This study investigated the effects of 1,25D and 25D on proliferation, 
differentiation and apoptosis in human osteosarcoma cell lines, SaOS-2 and 
143B.  Neither 25D nor 1,25D significantly affected proliferation in SaOS-2 or 
143B cells.  These studies suggest that 1,25D and 25D act as differentiation 
agents in human osteosarcoma cell lines through activation or upregulation of 
markers of osteoblastic differentiation, including ALP in 143B cells and 
mineralization in SaOS-2 and 143B cells.  Both 25D and 1,25D has a limited 
effect on apoptosis in SaOS-2 and 143B cells; 25D at high concentration may 
increase apoptosis in these cells. 
There are inherent differences in the biology of SaOS-2 and 143B 
osteosarcoma cells.  These differences in biology may modulate the cells’ 
response to 1,25D and 25D.  These studies need to be repeated with statistical 
power and validated in primary cultures of osteosarcoma, prior to testing in an 
animal model. 
 
Suggestions for Future Research 
 
1.  The use of isogenic cell lines to compare the effects of 25D and 
1,25D 
In the current study a metastatic p-53 null (SaOS-2) and highly metastatic, 
ras-gene transformed (143B) cell line were used to assess differences in 
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response to 1,25D or 25D.  However SaOS-2 and 143B differ genetically 
and thus cannot be compared.  Future studies should use isogenic cell 
lines to assess how differences in metastatic potential affect response to 
1,25D or 25D (i.e. 143B and its parent cell line, HOS). 
2. The use of supra-physiological concentrations of 1,25D or serum-
reduced medium 
The high percentage of serum (i.e. 10% FBS used in this study) used in 
most in vitro studies may be reducing the bioavailability of 1,25D in 
culture.  This should be addressed in the future by decreasing the 
percentage of FBS gradually and determining the minimal most effective 
concentration that is sufficient to support the growth of osteosarcoma cells 
in vitro.  At higher percentages of serum, supra-physiological 
concentrations of 25D or 1,25D may be necessary to induce similar 
effects. 
3. Morphology of apoptotic cells verified by Transmission Electron 
Microscopy (TEM) and Annexin-V staining 
Apoptotic cells need to be confirmed with further experiments outside of 
TUNEL in this study.  Analysis of morphology via TEM and Annexin-V 
staining may exclude a proportion of the cells as necrotic versus apoptotic. 
4. RT-PCR to detect osteoblastic differentiation markers 
There were issues in detecting osteocalcin secretion in SaOS-2 and 143B 
cells and varying results in other markers of differentiation. Expression of 
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markers of osteoblastic differentiation can be detected using Reverse 
Transcriptase Polymerase Chain Reaction (RT-PCR), a highly reputable 
method of assessing RNA expression.  These experiments are currently in 
progress. 
5. Relationship of VDR status in osteosarcoma cells and 1,25D or 25D 
effects on tumorigenicity.  
The VDR statuses of SaOS-2 and 143B cells are unknown and may have 
an effect on the responses of the cells to 1,25D and 25D.  Future research 
should test the expression of VDR in these cells and the associated 
response or lack thereof.   
6. Investigation into mechanisms of apoptosis----caspase or BAX 
mediated? 
Investigation of the 1,25D-regulated signaling pathways should be studied 
as a variety of pathways and proteins may be involved in apoptosis.  In 
breast cancer cells, 1,25D induces apoptosis via a novel caspase- and 
p53 independent pathway that can be inhibited by bcl-2 (18). Conversely, 
in human osteosarcoma cells 1,25D upregulates bcl-2 and this pathway, 
protecting the cells from apoptosis (23, 34).  
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CHAPTER 6 SUMMARY 
 
 
FIGURE 13. Working model of 1,25D and 25D effects on proliferation, 
differentiation, and apoptosis of osteosarcoma cell lines 
 
*No inhibition of cellular proliferation was observed in the current study.  In some 
cases, proliferation was increased in the presence of 25D. 
**In the current study differentiation was measured by alkaline phosphatase 
enzyme activity, osteocalcin secretion and in vitro mineralization.  In the 
presence of 1,25D in higher concentration in 143B, alkaline phosphatase activity 
was increased.  Mineralization was induced dose dependently in both SaOS-2 
and 143B cells.  Osteocalcin secretion was unable to be measured. 
†Apoptosis was induced by 25D at 1000nM in both SaOS-2 and 143B but 1,25D 
and 25D at other concentrations had no effect on apoptosis. 
OR 
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ABSTRACT 
 
INTRODUCTION: Osteosarcoma is a malignant bone tumor predominantly 
affecting children and adolescents. Osteosarcoma has a 60-70% survival rate 
with current treatments; hence there is a need to identify novel therapeutic 
regimens. The active form of vitamin D, 1α,25-dihydroxyvitamin D3 (1,25D), is 
being increasingly recognized for its anti-cancer properties. We examined the 
dose-response of 1,25D and 25-hydroxyvitamin D3 (25D) on human 
osteosarcoma cell lines, SaOS-2 (tumorigenic, p53 null, weakly metastatic) and 
143B (tumorigenic, ras gene transformed and highly metastatic). We 
hypothesized that vitamin D would inhibit proliferation and stimulate 
differentiation of these cells in a dose-dependent manner.  
 
METHODS: Osteosarcoma cell lines, SaOS-2 and 143B, were treated with 1,25D 
or 25D at concentrations 1-1000nM. Cellular proliferation was measured after 
exposure to vitamin D using a cell viability assay (MTS-tetrazolium), Ki67 
immunocytochemistry and cell cycle analysis by flow cytometry. Osteoblastic 
differentiation was measured by alkaline phosphatase (ALP) enzyme activity.  
 
RESULTS: In 143B cells, proliferation was increased significantly (p value < 0.05; 
Student’s t-Test) in cells exposed to 25D at 1000nM versus control, but vitamin D 
at other concentrations had no effect on proliferation or on cell cycle. In cells 
treated with 1,25D at higher concentrations ALP activity was increased 
significantly versus control. In SAOS-2 cells, vitamin D did not significantly inhibit 
proliferation, induce cell cycle changes or modify ALP activity versus control. We 
also observed biological differences between SAOS-2 vs. 143B control cells. Cell 
cycle analysis revealed significant differences including more SAOS-2 control 
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cells in G0/G1 than 143B, and significantly fewer SAOS-2 cells in synthesis 
phase than 143B. SAOS-2 control cells had alkaline phosphatase activity levels 
at least 8X (≥) higher than 143B cells.  
 
CONCLUSIONS: These findings show that there are inherent differences in the 
biology of SAOS-2 and 143B osteosarcoma cells, which might modulate vitamin 
D response i.e. resisting the antiproliferative actions of vitamin D. These studies 
need to be validated in primary cultures of osteosarcoma, prior to testing in an 
animal model. 
 
 
